Biotechnology - Agenus

Filter

Current filters:

Agenus

Popular Filters

Agenus to acquire Switzerland’s 4-Antibody AG

14-01-2014

US biotech firm Agenus has entered into a definitive agreement to acquire 4-Antibody AG, a private Switzerland-headquartered…

4-Antibody AGAgenusBiotechnologyGITRMergers & AcquisitionsOncologyOX40

Agenus and VaxLogic licensing accord on QS-21 Stimulon adjuvant

Agenus and VaxLogic licensing accord on QS-21 Stimulon adjuvant

27-09-2013

US biotech firm Agenus has entered into a non-exclusive license agreement with VaxLogic, a subsidiary…

AgenusBiotechnologyLicensingNorth AmericaPharmLogicVaccinesVaxLogic

GlaxoSmithKline's cancer drug candidate fails endpoint in melanoma

05-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and partner US biotech firm Agenus (Nasdaq: AGEN) this morning…

AgenusBiotechnologyGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchVaccines

Agenus expands deal with GlaxoSmithKline; Nuron in-licenses vaccines

06-03-2012

US biotech firm Agenus (Nasdaq: AGEN) says it has amended the QS-21 license and manufacturing agreement…

AgenusAkshaya BioBiotechnologyGlaxoSmithKlineLicensingNuron BiotechPharmaceuticalVaccines

Agenus out-licenses Russian rights to cancer vaccine

20-12-2011

US biotech firm Agenus (Nasdaq: AGEN), known as Antigenics until January of this year, has entered into…

AgenusAntigenicsBiotechnologyChemRar Hi-TechEuropeLicensingNephrology and HepatologyNewVacOncologyOncophagePharmaceuticalResearch

Back to top